DOP065 Long-term cost-effectiveness of tight control for Crohn’s disease with adalimumab-based treatment: economic evaluation beyond 48 weeks of CALM trial
暂无分享,去创建一个
G. D'Haens | F. Baert | M. Skup | W. Reinisch | R. Panaccione | A. Armuzzi | G. Novacek | J. Colombel | R. Thakkar | J. Petersson | P. Bossuyt | A. Danalıoğlu | Scott J Johnson | A. Robinson | W. Lee | M. Buessing | S. Johnson | T. Van̆ásek | E. Neimark | W. Lee | M Buessing